Zavicefta has now been launched in the UK to treat serious aerobic Gram-negative infections caused by antibiotic resistant bacteria. The Pfizer drug is a fixed combination of avibactam, a new beta-lactamase inhibitor, and ceftazidime, an antibiotic belonging to the class of third generation cephalosporins which is already approved for use in the EU.
Researchers at the Universities of Dundee and Edinburgh in Scotland will be working with the pharmaceutical industry to improve understanding of the biological processes that could form the basis of new therapies to support tissue regeneration or repair. The National Phenotypic Screening Centre (NPSC) at the University of Dundee and the Medical Research Council Centre
NHS England announces three new specialised treatments are to be made available on the NHS for patients in England after initial rejection for funding back in December. Funding has been now been approved for second allogeneic haematopoietic stem cell transplants (also known as bone marrow transplants), with around 15 patients a year who suffer a
Figures published by NHS Improvement shows that NHS provider sector has generated a year-to-date deficit of £886 million, with the sector forecasting a year-end deficit of £873m. According to the regulator, NHS providers are “experiencing one of the most challenging winters on record” due to a huge increase in the demand for urgent and emergency
Digital heart scanning software created by HeartFlow that can assess the cause of chest pain, has been recommended for use on the NHS, with the potential of saving the health service millions. England and Wales’ cost effectiveness watchdog NICE says the HeartFlowFFRCT could replace currently used invasive procedures with software which produces a 3-D digital
In a study of mice and monkeys, NIH funded researchers showed that they could prevent and reverse some of the brain injury caused by the toxic form of a protein called tau. The results, published in Science Translational Medicine, suggest that the study of compounds, called tau antisense oligonucleotides, that are genetically engineered to block
The British Heart Foundation has estimated that approximately 620,000 people in the UK are potentially carrying a faulty gene that puts them at high risk sudden death, but the foundation warns majority of carriers are unaware. The charity also noted that an accurate figure could be much higher due to under diagnosis and undiscovered faulty
Roche’s Tecentriq has scored another positive opinion. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently accepted the immunotherapy drug into the Early Access to Medicines Scheme (EAMS) for the treatment advanced bladder cancer. The decision means that patients suffering from bladder cancer could have access to the drug while it awaits decision from
AstraZeneca has expanded a late-stage trial that assess a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy. The Phase III MYSTIC trial was originally designed to assess the benefit of durvalumab monotherapy and a combination of durvalumab
Allergan has stepped into the field of Parkinson’s disease with an option to acquire US-based neurodegenerative research group Lysosomal Therapeutics (LTI). LTI-291, LTI’s lead programme, is designed to stimulate the activity of glucocerebrosidase (GCase) in the brain, which is reduced in many lysosomal storage diseases because of mutations in the GBA1 gene.